Darrell Pardi

List of Publications by Year in Descending Order

216 papers	8,868 citations	53 h-index	88 g-index
228 ext. papers	10,490 ext. citations	5.8 avg, IF	6.46 L-index

#	Paper	IF	Citations
216	Microscopic colitis, checkpoint inhibitor colitis, and other miscellaneous inflammatory and structural disorders of the colon **2022**, 1354-1373		
215	SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. *Clinical Infectious Diseases*, **2021**, 72, 2132-2140	11.6	48
214	Medication use and microscopic colitis: a multicentre retrospective cohort study. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 1209-1215	6.1	6
213	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	2
212	Abnormal findings on abdominopelvic cross-sectional imaging in patients with microscopic colitis: a retrospective, multicenter study. *Scandinavian Journal of Gastroenterology*, **2021**, 1-7	2.4	
211	Kinetics of polymerase chain reaction positivity in patients with infection. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211050443	4.7	
210	Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection. *Expert Review of Anti-Infective Therapy*, **2021**, 1-7	5.5	2
209	Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. *Journal of Clinical Gastroenterology*, **2021**, 55, 542-547	3	7
208	RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. *Clinical Infectious Diseases*, **2021**, 73, e1613-e1620	11.6	12
207	Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection. *Clinical Infectious Diseases*, **2021**, 73, e1706-e1712	11.6	2
206	Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. *Gut*, **2021**,	19.2	3
205	Outcomes in Patients with SARS-CoV-2 and Coinfection. *Infection and Drug Resistance*, **2021**, 14, 1645-1648	4.1	7
204	Microscopic Colitis: A Concise Review for Clinicians. *Mayo Clinic Proceedings*, **2021**, 96, 1302-1308	6.4	2
203	Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. *Gastroenterology*, **2021**, 160, 1961-1969.e3	13.3	19
202	Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	1
201	Microscopic colitis. *Nature Reviews Disease Primers*, **2021**, 7, 39	51.1	4
200	Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis-a single-centre experience. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 217-218	6.1	0

199	Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. *Mayo Clinic Proceedings*, **2021**, 96, 1418-1425	6.4	3
198	The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	4
197	Clinical Characteristics and Treatment Response in Microscopic Colitis Based on Age at Diagnosis: A Multicenter Retrospective Study. *Digestive Diseases and Sciences*, **2021**, 1	4	0
196	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. *Inflammatory Bowel Diseases*, **2021**, 27, 594-602	4.5	2
195	Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 616-617	6.9	26
194	Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. *European Journal of Clinical Microbiology and Infectious Diseases*, **2021**, 40, 1383-1392	5.3	5
193	Novel risk factors and outcomes in inflammatory bowel disease patients with infection. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 1756284821997792	4.7	1
192	Efficacy of oral vancomycin prophylaxis for prevention of infection: a systematic review and meta-analysis. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 1756284821994046	4.7	2
191	Development of gastroenterology and transplant hepatology milestones 2.0: a guide for programs, faculty, and fellows. *American Journal of Gastroenterology*, **2021**, 116, 2009-2013	0.7	0
190	Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows. *Hepatology*, **2021**, 74, 2226-2232	11.2	1
189	Vulvar Crohn's Disease: Clinical Features and Outcomes. *American Journal of Gastroenterology*, **2021**, 116, 2296-2299	0.7	
188	Development of gastroenterology and transplant hepatology milestones 2.0: a guide for programs, faculty, and fellows. *Gastrointestinal Endoscopy*, **2021**, 94, 665-670	5.2	
187	Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide for Programs, Faculty, and Fellows. *Gastroenterology*, **2021**, 161, 1318-1324	13.3	
186	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 826-849	18.8	8
185	Reply. *Gastroenterology*, **2021**, 161, 1345	13.3	
184	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 1108-1117	6.1	2
183	In Search of the (Clostridium difficile) Holy Grail. *Clinical Infectious Diseases*, **2020**, 70, 1094-1095	11.6	2
182	Collagenous Colitis Is Associated With HLA Signature and Shares Genetic Risks With Other Immune-Mediated Diseases. *Gastroenterology*, **2020**, 159, 549-561.e8	13.3	15

181	Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era. *American Journal of Gastroenterology*, **2020**, 115, 971-974	0.7	19
180	Response to 'Comments on the published systematic review and meta-analysis on the increasing antibiotic resistance in Clostridioides difficile' by Kouhsari et al. *Anaerobe*, **2020**, 61, 102148	2.8	
179	Update on Treatment of Clostridioides difficile Infection. *Mayo Clinic Proceedings*, **2020**, 95, 758-769	6.4	17
178	Clostridium difficile Infection in the Emergency Department. *Journal of Clinical Gastroenterology*, **2020**, 54, 350-355	3	2
177	Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2020**, 26, 1415-1420	4.5	14
176	Incidence of infection in peripartum women: a retrospective cohort study. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820942621	4.7	
175	Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. *Mayo Clinic Proceedings*, **2020**, 95, 1632-1648	6.4	56
174	Microscopic Colitis, Collagenous and Lymphocytic **2020**, 567-574		
173	Reply to Lagier et al. *Clinical Infectious Diseases*, **2020**, 70, 2454-2455	11.6	
172	Reply to Khoruts and Sadowsky. *Clinical Infectious Diseases*, **2019**, 69, 2233-2234	11.6	1
171	Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. *Clinical Microbiology and Infection*, **2019**, 25, 958-963	9.5	42
170	Reply. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 572	6.9	
169	Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **2019**, 68, 1351-1358	11.6	78
168	The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. *Journal of Clinical Medicine*, **2019**, 8,	5.1	3
167	Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis. *Anaerobe*, **2019**, 58, 35-46	2.8	29
166	Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings. *Intestinal Research*, **2019**, 17, 434-437	4.1	2
165	Pouchitis After Restorative Proctocolectomy **2019**, 187-195		
164	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. *Crohn's & Colitis 360*, **2019**, 1,	1.4	2

163	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *The Cochrane Library*, **2019**, 5, CD001176	5.2	12
162	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *The Cochrane Library*, **2019**, 11, CD001176	5.2	9
161	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. *Gastrointestinal Endoscopy*, **2019**, 89, 215-237	5.2	37
160	Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. *Inflammatory Bowel Diseases*, **2019**, 25, 610-619	4.5	11
159	Reply to Davido et al. *Clinical Infectious Diseases*, **2018**, 66, 483-485	11.6	
158	Presence of immune deficiency increases the risk of hospitalization in patients with norovirus infection. *Diagnostic Microbiology and Infectious Disease*, **2018**, 90, 300-306	2.9	4
157	Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1607-1615.e1	6.9	49
156	Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. *Gut*, **2018**, 67, 441-446	19.2	23
155	Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. *Journal of Clinical Gastroenterology*, **2018**, 52, 151-154	3	27
154	Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. *Journal of Clinical Gastroenterology*, **2018**, 52, 146-150	3	31
153	Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. *Clinical Infectious Diseases*, **2018**, 66, 514-522	11.6	26
152	Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 528-533	6.9	17
151	Screening for Clostridium difficile colonization on admission to a hematopoietic stem cell transplant unit may reduce hospital-acquired C difficile infection. *American Journal of Infection Control*, **2018**, 46, 459-461	3.8	14
150	uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. *Science Translational Medicine*, **2018**, 10,	17.5	73
149	Statin use and the risk of infection: a systematic review with meta-analysis. *Infection and Drug Resistance*, **2018**, 11, 405-416	4.2	6
148	Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. *Inflammatory Bowel Diseases*, **2018**, 24, 1582-1588	4.5	20
147	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. *Gastrointestinal Endoscopy*, **2018**, 88, 360-369.e2	5.2	15
146	Current Approach to the Evaluation and Management of Microscopic Colitis. *Current Gastroenterology Reports*, **2017**, 19, 8	5	16

145	The surgical management of inflammatory bowel disease. *Current Problems in Surgery*, **2017**, 54, 172-250	2.8	4
144	Immune modulator therapy for microscopic colitis in a case series of 73 patients. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 169-174	6.1	27
143	Diagnosis and Management of Microscopic Colitis. *American Journal of Gastroenterology*, **2017**, 112, 78-85	5.7	80
142	Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. *Microbiome*, **2017**, 5, 55	16.6	74
141	Fecal microbiota transplantation for gastrointestinal disorders. *Current Opinion in Gastroenterology*, **2017**, 33, 8-13	3	22
140	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Infection: A Nationwide Analysis. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 466-472	7.3	15
139	Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. *JAMA Internal Medicine*, **2017**, 177, 784-791	11.5	84
138	Extended-release Multimatrix Budesonide for Microscopic Colitis. *Inflammatory Bowel Diseases*, **2017**, 23, E21-E22	4.5	4
137	Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 850-856	6.9	18
136	Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease. *Gastroenterology Clinics of North America*, **2017**, 46, 589-601	4.4	2
135	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Reduces Recurrent Urinary Tract Infection Frequency. *Clinical Infectious Diseases*, **2017**, 65, 1745-1747	11.6	64
134	Experience and Outcomes at a Specialized Clinical Practice. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2017**, 1, 49-56	3.1	13
133	Outcomes in Patients with Recurrent Clostridium Difficile Infection Treated with Vancomycin Taper. *Gastroenterology*, **2017**, 152, S348	13.3	4
132	Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. *Journal of Clinical Gastroenterology*, **2017**, 51, 228-234	3	20
131	The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 1240-1247	2.4	12
130	Case report: Pentoxifylline treatment in microscopic colitis. *Medicine (United States)*, **2017**, 96, e8355	1.8	1
129	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. *Mayo Clinic Proceedings*, **2017**, 92, 1617-1624	6.4	39
128	Chronic Diarrhea: Diagnosis and Management. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 182-193.e3	6.9	87

127	Letter: the definition of budesonide dependence in microscopic colitis-authors' reply. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 636	6.1	
126	Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis. *Open Forum Infectious Diseases*, **2017**, 4, S384-S384	1	78
125	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. *Gastrointestinal Endoscopy*, **2016**, 83, 1005-12	5.2	32
124	High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 576-82	6.1	68
123	990 Cumulative Probability and Outcomes of Anti-Tumor Necrosis Factor Use in Patients With Crohn's Disease: A Population-Based Study. *Gastroenterology*, **2016**, 150, S202-S203	13.3	2
122	Outcomes in children with Clostridium difficile infection: results from a nationwide survey. *Gastroenterology Report*, **2016**, 4, 293-298	3.3	10
121	Validation of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 777-8	6.9	6
120	American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis. *Gastroenterology*, **2016**, 150, 247-274.e11	13.3	24
119	Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. *Clinical Infectious Diseases*, **2016**, 62, 596-602	11.6	98
118	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. *Journal of Infectious Diseases*, **2016**, 214, 173-81	7	205
117	Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 1145-1152	4.2	22
116	Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection. *Internal and Emergency Medicine*, **2016**, 11, 657-65	3.7	28
115	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. *Blood*, **2016**, 128, 3599-3599	2.2	
114	Clostridium difficile infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. *Colorectal Disease*, **2016**, 18, O154-7	2.1	7
113	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. *Digestive Diseases and Sciences*, **2016**, 61, 2627-35	4	12
112	New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation. *American Journal of Gastroenterology*, **2016**, 111, 751-2	0.7	24
111	Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 715-727	6.1	63
110	Tu1381 Genome-Wide Association Identifies Multiple Collagenous Colitis Susceptibility Loci. *Gastroenterology*, **2015**, 148, S-875	13.3	4

109	Su1353 Outcomes of Patients With Microscopic Colitis Treated With Bismuth Subsalicylate. *Gastroenterology*, **2015**, 148, S-483	13.3	4
108	Chronic Diarrhea **2015**, 209-223		1
107	Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1719-27	27.4	213
106	Letter: clinical predictors of Clostridium difficile infection - advanced age and residential status are important factors for prediction and prevention - authors' reply. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 233	6.1	
105	Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. *Gastroenterology*, **2015**, 148, 64-76.e2; quiz e14	13.3	80
104	Epidemiology, risk factors and management of cardiovascular diseases in IBD. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 26-35	24.2	66
103	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *The Cochrane Library*, **2015**, CD001176	5.2	45
102	Extraintestinal Clostridium difficile infections: a single-center experience. *Mayo Clinic Proceedings*, **2014**, 89, 1525-36	6.4	27
101	Update on anti-tumor necrosis factor agents in Crohn disease. *Gastroenterology Clinics of North America*, **2014**, 43, 457-78	4.4	31
100	Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. *American Journal of Gastroenterology*, **2014**, 109, 924-5	0.7	8
99	The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 838-42	6.9	77
98	Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. *American Journal of Gastroenterology*, **2014**, 109, 401-8	0.7	42
97	Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 382-93.e1: quiz e22	6.9	149
96	Microscopic colitis. *Clinics in Geriatric Medicine*, **2014**, 30, 55-65	3.8	9
95	Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 210-8	6.9	126
94	1620Extraintestinal Clostridium difficile infections: A Single Center Experience. *Open Forum Infectious Diseases*, **2014**, 1, S433-S433	1	78
93	Clostridium difficile infection: management strategies for a difficult disease. *Therapeutic Advances in Gastroenterology*, **2014**, 7, 72-86	4.7	35
92	Gastro 2013 APDW/WCOG Shanghai working party report: chronic diarrhea: definition, classification, diagnosis. *Journal of Gastroenterology and Hepatology (Australia)*, **2014**, 29, 6-25	4	46

91	Reply: To PMID 23978350. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 2135	6.9	
90	Clinical predictors of recurrent Clostridium difficile infection in out-patients. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 518-22	6.1	24
89	Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. *Mayo Clinic Proceedings*, **2014**, 89, 1621-35	6.4	61
88	Clinical factors associated with development of severe-complicated Clostridium difficile infection. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 1466-71	6.9	47
87	Appendectomy is not associated with adverse outcomes in clostridium difficile infection: a population-based study. *American Journal of Gastroenterology*, **2013**, 108, 626-7	0.7	11
86	The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 977-87	6.1	16
85	Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 49-54.e1	6.9	95
84	The epidemiology of Clostridium difficile infection in children: a population-based study. *Clinical Infectious Diseases*, **2013**, 56, 1401-6	11.6	158
83	Clinical features and treatment responses in pediatric lymphocytic and collagenous colitis. *Journal of Pediatric Gastroenterology and Nutrition*, **2013**, 57, 557-61	2.8	10
82	Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. *Inflammatory Bowel Diseases*, **2013**, 19, 2394-9	4.5	57
81	Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids. *Inflammatory Bowel Diseases*, **2013**, 19, 2644-51	4.5	6
80	Acute kidney injury is an independent marker of severity in Clostridium difficile infection: a nationwide survey. *Journal of Clinical Gastroenterology*, **2013**, 47, 481-4	3	16
79	Meta-analysis: serological markers and the risk of acute and chronic pouchitis. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 867-75	6.1	37
78	Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. *American Journal of Gastroenterology*, **2013**, 108, 256-9	0.7	50
77	Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. *Inflammatory Bowel Diseases*, **2013**, 19, 550-3	4.5	37
76	Management of the elderly patients with inflammatory bowel disease: practical considerations. *Inflammatory Bowel Diseases*, **2013**, 19, 2257-72	4.5	17
75	Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. *Inflammatory Bowel Diseases*, **2013**, 19, 1631-8	4.5	57
74	Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. *Inflammatory Bowel Diseases*, **2012**, 18, 219-25	4.5	56

73	Gastric acid suppression and Clostridium difficile infection: is there a causal connection?. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 564; author reply 564	6.9	7
72	Non-IBD colitides (eosinophilic, microscopic). *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2012**, 26, 611-22	2.5	14
71	Mo1116 The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial. *Gastroenterology*, **2012**, 142, S-599	13.3	7
70	Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. *Mayo Clinic Proceedings*, **2012**, 87, 636-42	6.4	48
69	Clostridium difficile infection in patients with chronic kidney disease. *Mayo Clinic Proceedings*, **2012**, 87, 1046-53	6.4	55
68	Clostridium difficile infection: new insights into management. *Mayo Clinic Proceedings*, **2012**, 87, 1106-17	6.4	98
67	Autoimmune enteropathy: a review and update of clinical management. *Current Gastroenterology Reports*, **2012**, 14, 380-5	5	94
66	Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. *Inflammatory Bowel Diseases*, **2012**, 18, 2203-8	4.5	31
65	Outcomes in community-acquired Clostridium difficile infection. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 613-8	6.1	59
64	Miscellaneous colitides. *Current Opinion in Gastroenterology*, **2012**, 28, 76-81	3	8
63	The epidemiology of community-acquired Clostridium difficile infection: a population-based study. *American Journal of Gastroenterology*, **2012**, 107, 89-95	0.7	420
62	"Community-acquired Clostridium difficile infection: an emerging entity". *Clinical Infectious Diseases* , **2012**, 55, 1741-2	11.6	16
61	An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. *Journal of Clinical Gastroenterology*, **2012**, 46, 846-9	3	28
60	Microscopic colitis. *Gastroenterology*, **2011**, 140, 1155-65	13.3	186
59	Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). *American Journal of Gastroenterology*, **2011**, 106, 1889-97	0.7	79
58	Review article: Microscopic colitis--lymphocytic, collagenous and 'mast cell' colitis. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 21-32	6.1	39
57	Microscopic colitis and disease associations: authors reply. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 820-821	6.1	
56	Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. *Digestive Diseases and Sciences*, **2011**, 56, 569-77	4	24

55	Review of the microscopic colitides. *Current Gastroenterology Reports*, **2011**, 13, 458-64	5	51
54	Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. *Inflammatory Bowel Diseases*, **2011**, 17, 1257-64	4.5	37
53	High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2011**, 106, 1638-45	0.7	177
52	Microscopic Colitis **2010**, 321-325		
51	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Cochrane Database of Systematic Reviews*, **2010**, CD001176		80
50	413 Age is not Associated With Adverse Events From Biologic Therapy in Patients With Inflammatory Bowel Disease. *Gastroenterology*, **2010**, 138, S-62	13.3	10
49	The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. *Expert Review of Gastroenterology and Hepatology*, **2010**, 4, 409-16	4.2	124
48	Inflammatory bowel disease in the elderly. *Drugs and Aging*, **2010**, 27, 617-24	4.7	25
47	Assessment of appropriateness of indications for CT enterography in younger patients. *Inflammatory Bowel Diseases*, **2010**, 16, 226-32	4.5	34
46	Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. *Inflammatory Bowel Diseases*, **2010**, 16, 1912-21	4.5	40
45	Microscopic Colitis **2010**, 93-103		
44	Pouchitis after Restorative Proctocolectomy **2010**, 248-256		
43	The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. *American Journal of Gastroenterology*, **2009**, 104, 1468-74	0.7	29
42	After budesonide, what next for collagenous colitis?. *Gut*, **2009**, 58, 3-4	19.2	17
41	Observer variability in the histologic diagnosis of microscopic colitis. *Inflammatory Bowel Diseases*, **2009**, 15, 35-8	4.5	39
40	Clinical guidelines for the management of pouchitis. *Inflammatory Bowel Diseases*, **2009**, 15, 1424-31	4.5	98
39	Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. *American Journal of Roentgenology*, **2009**, 193, 113-21	5.4	313
38	Patients with drug-induced microscopic colitis should not be included in controlled trials assessing the efficacy of anti-inflammatory drugs in microscopic colitis. *Gastroenterology*, **2009**, 137, 1535-6	13.3	5

37	T1193 A Randomized, Double-Blind, Placebo-Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis. *Gastroenterology*, **2009**, 136, A-519-A-520	13.3	21
36	Microscopic Colitis. *Frontiers of Gastrointestinal Research*, **2009**, 135-145		1
35	Comparison Between Community Acquired and Hospital Acquired Clostridium difficile Infection: A Population-based Study. *American Journal of Gastroenterology*, **2009**, 104, S183	0.7	2
34	841 The Natural History of Microscopic Colitis Treated with Corticosteroids. *Gastroenterology*, **2008** , 134, A-121-A-122	13.3	9
33	S1211 Clinical Benefit of CT Enterography in Suspected or Established Crohn's Disease: Impact On Patient Management and Physician Level of Confidence. *Gastroenterology*, **2008**, 134, A-202	13.3	5
32	Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. *Gastrointestinal Endoscopy*, **2008**, 68, 255-66	5.2	283
31	Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. *American Journal of Gastroenterology*, **2008**, 103, 2015-22	0.7	158
30	Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus. *American Journal of Gastroenterology*, **2008**, 103, 842-9	0.7	22
29	Endoscopy in the management of patients after ileal pouch surgery for ulcerative colitis. *Endoscopy* , **2008**, 40, 529-33	3.4	27
28	Recurrent Clostridium difficile infection: an immunodeficiency state?. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 672-3	6.9	7
27	Adult autoimmune enteropathy: Mayo Clinic Rochester experience. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 1282-90; quiz 1245	6.9	177
26	Symptomatic overlap between irritable bowel syndrome and microscopic colitis. *Inflammatory Bowel Diseases*, **2007**, 13, 175-81	4.5	125
25	The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. *Gut*, **2007**, 56, 504-8	19.2	180
24	Inflammatory bowel disease in the elderly. *Aging Health*, **2007**, 3, 77-84		5
23	Systematic review: the management of pouchitis. *Alimentary Pharmacology and Therapeutics*, **2006**, 23, 1087-96	6.1	88
22	Microscopic colitis is not associated with cholecystectomy or appendectomy. *Inflammatory Bowel Diseases*, **2006**, 12, 708-11	4.5	12
21	Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. *Inflammatory Bowel Diseases*, **2006**, 12, 29-32	4.5	43
20	Utility of symptom-based criteria for evaluating patients with chronic diarrhea. *Gastrointestinal Endoscopy*, **2005**, 62, 649	5.2	1

19	Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. *Alimentary Pharmacology and Therapeutics*, **2005**, 22, 277-84	6.1	205
18	Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. *Gut* , **2005**, 54, 321-2	19.2	33
17	Should the national GI fellowship matching program be restored?. *American Journal of Gastroenterology*, **2004**, 99, 1411-2	0.7	12
16	Microscopic colitis: an update. *Inflammatory Bowel Diseases*, **2004**, 10, 860-70	4.5	58
15	Clinical management of pouchitis. *Gastroenterology*, **2004**, 127, 1809-14	13.3	51
14	Colonic ulcers accompanying collagenous colitis: implication of nonsteroidal anti-inflammatory drugs. *American Journal of Gastroenterology*, **2003**, 98, 1834-7	0.7	101
13	Microscopic colitis. *Mayo Clinic Proceedings*, **2003**, 78, 614-6; quiz 616-7	6.4	13
12	Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterology*, **2003**, 124, 889-93	13.3	446
11	Paraneoplastic dysmotility: loss of interstitial cells of Cajal. *American Journal of Gastroenterology*, **2002**, 97, 1828-33	0.7	64
10	Lymphocytic colitis: clinical features, treatment, and outcomes. *American Journal of Gastroenterology*, **2002**, 97, 2829-33	0.7	126
9	Microscopic colitis: a review. *American Journal of Gastroenterology*, **2002**, 97, 794-802	0.7	107
8	Treatment of inflammatory bowel disease in the elderly: an update. *Drugs and Aging*, **2002**, 19, 355-63	4.7	26
7	Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. *Gastroenterology*, **2001**, 120, 1483-4	13.3	125
6	Treatment outcomes in lymphocytic collitis. *Gastroenterology*, **2001**, 120, A13	13.3	4
5	Clostridium difficile-associated diarrhea and colitis. *Mayo Clinic Proceedings*, **2001**, 76, 725-30	6.4	53
4	Re: Kreiss et al.: Pneumatosis intestinalis complicating C. difficile pseudomembranous colitis. *American Journal of Gastroenterology*, **2000**, 95, 1107	0.7	2
3	Early measles virus infection is associated with the development of inflammatory bowel disease. *American Journal of Gastroenterology*, **2000**, 95, 1480-5	0.7	24
2	Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. *Inflammatory Bowel Diseases*, **1999**, 5, 104-6	4.5	13